[Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient].
METHODS
A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects.


CONCLUSIONS
Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established.
Ramírez-Soria
M P
MP
Departamento de Optica, Hospital Universitario La Fe, Valencia, España. piraso2001@yahoo.es
España-Gregori
E
E
Aviñó-Martínez
J
J
Pastor-Pascual
F
F
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001762:Blepharitis / Q000139:chemically induced*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab